|
|
41
|
|
|
B4911
|
|
|
XOLAIR 150MG INJ (NVS) OMALIZUMAB (C)
|
|
|
OMALIZUMAB
|
|
|
XOLAIR
|
|
|
150MG VIAL
|
|
|
C
|
|
|
1304.93
|
|
|
1304.9314
|
|
|
150MG
|
|
|
VIAL
|
|
|
0
|
|
|
VIAL
|
|
|
NVS
|
|
|
NOVARTIS CARIBE SA
|
|
|
COL
|
|
|
COLLINS LTD
|
|
|
|
|
|
|
|
|
2024-04-01
|
|
|
2026-03-31
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
N
|
|
|
4810
|
|
|
RESPIRATORY INFLAMMATORY AGENTS
|
|
|
|
|
|
IV
|
|
|
0
|
|
|
RESPIRATORY INFLAMMATORY AGENTS
|
|
|
|